Thymus and activation-regulated chemokine (TARC/CCL17) predicts decline of pulmonary function in patients with chronic obstructive pulmonary disease
Thymus and activation-regulated chemokine (TARC/CCL17) predicts decline of pulmonary function in patients with chronic obstructive pulmonary disease
复制标题
DOI：
10.1016/j.alit.2020.04.004
复制
发表时间：
2021-01-01
影响因子：
6.8
通讯作者：
Watanabe, Masafumi
中科院分区：
文献类型：
--
作者：
Machida, Hiroyoshi;Inoue, Sumito;Watanabe, Masafumi
背景：慢性阻塞性肺疾病(COPD)患者肺功能恶化，如FEV1下降，与预后不良密切相关。然而，很少有研究阐明用于预测肺功能下降的有用生物标志物。我们评估了胸腺和Th2炎症标志物活化调节趋化因子(TARC)能否预测COPD患者FEV1的快速下降。方法：我们招募了161名COPD稳定期患者，每6个月进行一次肺功能测试。在注册时，进行了血液测试，包括血清TARC水平。我们评估了肺功能测试参数的变化与血清TARC水平之间的相关性。以FEV1年变化第25个百分位数或FEV1预测百分比(%FEV1)判定肺功能快速下降。结果：FEV1快速下降组的病情加重频率、肺气肿程度及血清TARC水平均高于非快速下降组。当以%FEV1代替FEV1、年龄作为分类指标时，快速下降组的病情加重次数、肺气肿程度及血清TARC水平均显著高于非快速下降组。单因素Logistic回归分析显示，TARC是快速下降组的显著预测因素。在校正肺气肿的多因素分析中，血清TARC水平是快速下降组的独立预测因素。结论：TARC是FEV1快速下降的独立预测生物标志物。通过检测血清TARC水平可以预测FEV1下降的风险，从而有助于COPD患者的治疗。版权所有(C)2020，日本过敏学会。爱思唯尔B.V.制作和主办。
Background: The deterioration of pulmonary function, such as FEV1-decline, is strongly associated with poor prognosis in patients with chronic obstructive pulmonary disease (COPD). However, few investigations shed light on useful biomarkers for predicting the decline of pulmonary function. We evaluated whether thymus and activation-regulated chemokine (TARC), a Th2 inflammation marker, could predict rapid FEV1-decline in COPD patients.Methods: We recruited 161 patients with stable COPD and performed pulmonary function test once every six months. At the time of registration, blood tests, including serum levels of TARC were performed. We assessed the correlation between changes in parameters of pulmonary function tests and serum levels of TARC. The rapid-decline in pulmonary function was determined using 25th percentile of change in FEV1 or FEV1 percent predicted (%FEV1) per year.Results: In the FEV1-rapid-decline group, the frequency of exacerbations, the degree of emphysema, and serum levels of TARC was higher than in the non-rapid-decline group. When using %FEV1 as a classifier instead of FEV1, age, the frequency of exacerbations, the degree of emphysema and serum levels of TARC in the rapid-decline group was significantly greater than those in the non-rapid-decline group. In univariate logistic regression analysis, TARC was the significant predictive factor for rapid-decline group. In multivariate analysis adjusted for emphysema, serum levels of TARC are independently significant predicting factors for the rapid-decline group.Conclusions: TARC is an independent predictive biomarker for the rapid-decline in FEV1. Measuring serum TARC levels may help the management of COPD patients by predicting the risk of FEV1 decline. Copyright (c) 2020, Japanese Society of Allergology. Production and hosting by Elsevier B.V.